Atorvastatin had no effect on the single components of the primary endpoint with the exception of fatal stroke, in which RR was 2.03 (95% CI 1.05- 3.93; p 0.04). The secondary endpoint of combined cardiac events (RR 0.82; 95% CI 0.68 0.99; p 0.03) was significantly reduced, but not all combined cerebrovascular events (RR 95% CI 0.79 1.08; p 0.33). AURORA Study (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Dialysis: an Assessment of Survival and Cardiovascular Events) In this international double-blind randomized trial, 2776 HD patients were assigned to receive rosuvastatin 10 mg daily or placebo, and followed for a median of 3.8 years.44 Despite the mean reduction in LDL-C of 43% in the intervention group, the combined primary endpoint of death from cardiovascular causes, nonfatal MI, or nonfatal stroke was not reduced (HR 0.96; 95% CI 0.84 1.11; p 0.59). Rosuvastatin did not reduce the risk of individual components of the primary endpoint, nor of all-cause mortality (HR 0.96; 95% CI 0.86- 1.07; p 0.51). SHARP (Study of Heart and Renal Protection) This international double-blind randomized trial assigned 9270 participants Z40 years old with CKD to receive simvastatin 20 mg plus ezetimibe 10 mg daily or placebo, and followed them for 4.9 years.14 Thirty-three percent of the patients (n 3023) were receiving maintenance dialysis at randomization. The remaining 6247 CKD patients had a . Mean reduction in LDL-C among the treatment group was 0.83 mmol/l (32 mg/dl), compared to placebo. Statin plus ezetimibe therapy was associated with a significant 17% RR reduction of the primary outcome of major atherosclerotic events (coronary death, MI, non-hemorrhagic stroke, or any revascularization) compared with placebo (HR 0.83; 95% CI 0.74 0.94). 